Catch and release: freeing up PD-L1 ameliorates autoimmunity

  • Nat Immunol. 2022 Mar;23(3):344-346. doi: 10.1038/s41590-022-01140-2.
Stephanie Grebinoski  #  1  2  3 ,  Angela M Gocher-Demske  #  1  3 ,  Dario A A Vignali  #  4  5  6
Affiliations
  • 1. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • 2. Graduate Program of Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • 3. Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • 4. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. [email protected].
  • 5. Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. [email protected].
  • 6. Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. [email protected].
  • # Contributed equally.
PMID: 35190718 DOI: 10.1038/s41590-022-01140-2
Abstract

The binding of PD-L1 to CD80 on antigen-presenting cells prevents PD-1 ligation on T cells. Therapeutic blockade of the cis-PD-L1–CD80 interaction liberates PD-L1 to bind to PD-1, inhibits autoreactive T cells and robustly alleviates autoimmune symptoms.

Products